Synthesis, Antimycobacterial Activity and In Vitro Cytotoxicity of 5-Chloro-N-phenylpyrazine-2-carboxamides

5-Chloropyrazinamide (5-Cl-PZA) is an inhibitor of mycobacterial fatty acid synthase I with a broad spectrum of antimycobacterial activity in vitro. Some N-phenylpyrazine-2-carboxamides with different substituents on both the pyrazine and phenyl core possess significant in vitro activity against Mycobacterium tuberculosis. To test the activity of structures combining both the 5-Cl-PZA and anilide motifs a series of thirty 5-chloro-N-phenylpyrazine-2-carboxamides with various substituents R on the phenyl ring were synthesized and screened against M. tuberculosis H37Rv, M. kansasii and two strains of M. avium. Most of the compounds exerted activity against M. tuberculosis H37Rv in the range of MIC = 1.56–6.25 µg/mL and only three derivatives were inactive. The phenyl part of the molecule tolerated many different substituents while maintaining the activity. In vitro cytotoxicity was decreased in compounds with hydroxyl substituents, preferably combined with other hydrophilic substituents. 5-Chloro-N-(5-chloro-2-hydroxyphenyl)pyrazine-2-carboxamide (21) inhibited all of the tested strains (MIC = 1.56 µg/mL for M. tuberculosis; 12.5 µg/mL for other strains). 4-(5-Chloropyrazine-2-carboxamido)-2-hydroxybenzoic acid (30) preserved good activity (MIC = 3.13 µg/mL M. tuberculosis) and was rated as non-toxic in two in vitro models (Chinese hamster ovary and renal cell adenocarcinoma cell lines; SI = 47 and 35, respectively).

[1]  M. Doležal,et al.  Synthesis and antimycobacterial evaluation of N-substituted 5-chloropyrazine-2-carboxamides. , 2013, Bioorganic & medicinal chemistry letters.

[2]  M. Lourenço,et al.  Synthesis and Antitubercular Evaluation of N-Arylpyrazine and N,N′-Alkyl-diylpyrazine-2-carboxamide Derivatives. , 2013 .

[3]  M. Doležal,et al.  Synthesis and antimycobacterial evaluation of pyrazinamide derivatives with benzylamino substitution. , 2013, Bioorganic & medicinal chemistry letters.

[4]  W. Jacobs,et al.  Analogs of the Antituberculous Agent Pyrazinamide Are Competitive Inhibitors of NADPH Binding to M. tuberculosis Fatty Acid Synthase I , 2012, Chemistry & biodiversity.

[5]  W. Jacobs,et al.  Activity of 5-chloro-pyrazinamide in mice infected with Mycobacterium tuberculosis or Mycobacterium bovis , 2012, The Indian journal of medical research.

[6]  M. Doležal,et al.  Substituted N-Benzylpyrazine-2-carboxamides: Synthesis and Biological Evaluation † , 2012, Molecules.

[7]  J. Jampílek,et al.  Pyrazinecarboxylic Acid Derivatives with Antimycobacterial Activity , 2012 .

[8]  P. Cardona Understanding Tuberculosis - New Approaches to Fighting Against Drug Resistance , 2012 .

[9]  P. Wangikar,et al.  Protective effect of curcumin, silymarin and N-acetylcysteine on antitubercular drug-induced hepatotoxicity assessed in an in vitro model , 2012, Human & experimental toxicology.

[10]  M. Doležal,et al.  Antimycobacterial evaluation of pyrazinoic acid reversible derivatives. , 2011, Current pharmaceutical design.

[11]  P. Wangikar,et al.  Studies on toxicity of antitubercular drugs namely isoniazid, rifampicin, and pyrazinamide in an in vitro model of HepG2 cell line , 2011, Medicinal Chemistry Research.

[12]  W. Peters,et al.  Isoniazid and its toxic metabolite hydrazine induce in vitro pyrazinamide toxicity. , 2008, International journal of antimicrobial agents.

[13]  J. N. Low,et al.  Patterns of hydrogen bonding in mono- and di-substituted N-arylpyrazinecarboxamides. , 2008, Acta crystallographica. Section B, Structural science.

[14]  A. J. van der Ven,et al.  Antituberculosis drug‐induced hepatotoxicity: Concise up‐to‐date review , 2008, Journal of gastroenterology and hepatology.

[15]  W. Jacobs,et al.  Inhibition of Isolated Mycobacterium tuberculosis Fatty Acid Synthase I by Pyrazinamide Analogs , 2007, Antimicrobial Agents and Chemotherapy.

[16]  D. Mitchison,et al.  The curious characteristics of pyrazinamide: a review. , 2003, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[17]  Clifton E. Barry,et al.  Effects of Pyrazinamide on Fatty Acid Synthesis by Whole Mycobacterial Cells and Purified Fatty Acid Synthase I , 2002, Journal of bacteriology.

[18]  William R. Jacobs,et al.  Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis , 2000, Nature Medicine.

[19]  M. Cynamon,et al.  In Vitro Antimycobacterial Activity of 5-Chloropyrazinamide , 1998, Antimicrobial Agents and Chemotherapy.

[20]  R. Jones,et al.  Optimal dilution susceptibility testing conditions, recommendations for MIC interpretation, and quality control guidelines for the ampicillin-sulbactam combination , 1987, Journal of clinical microbiology.

[21]  E. Bruck,et al.  National Committee for Clinical Laboratory Standards. , 1980, Pediatrics.